ALEC Alector, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1653087 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY151.1%
TTM net income YoY138.4%
TTM EPS YoY134.0%
Revenue 3-yr CAGR21.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin20.2%
Net margin23.9%
FCF margin-86.5%
EBITDA margin22.6%
Returns
ROE47.5%
ROA16.5%
ROIC (approx.)217.2%
Asset turnover0.69x
Leverage & solvency
Liabilities / assets29.7%
Debt / equity0.00x
Current ratio4.10x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-3.62x
Accruals ratio76.4%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $162.87M | $3.32M | $1.05M | $6.24M | $3.26M | $7.87M | $3.67M | $54.28M |
| R&D expense | $30.03M | $19.46M | $17.86M | $32.46M | $29.35M | $27.61M | $33.64M | $46.46M |
| SG&A expense | $8.99M | $8.25M | $8.11M | $13.34M | $11.52M | $14.40M | $14.73M | $15.03M |
| Operating income | $123.84M | -$24.39M | -$24.92M | -$39.57M | -$37.61M | -$34.14M | -$44.70M | -$7.25M |
| Pretax income | $124.66M | -$22.86M | -$22.93M | -$37.10M | -$34.67M | -$30.52M | -$40.47M | -$2.00M |
| Income tax | $60,000 | $130,000 | $0 | $168,000 | $0 | $0 | $0 | $48,000 |
| Net income | $124.60M | -$22.99M | -$22.93M | -$37.27M | -$34.67M | -$30.52M | -$40.47M | -$2.07M |
| EBITDA | $124.82M | -$23.34M | -$23.84M | -$38.40M | -$36.37M | -$31.81M | -$43.71M | -$6.01M |
| EPS (basic) | 1.11 | -0.21 | -0.21 | — | -0.34 | -0.30 | -0.41 | — |
| EPS (diluted) | 1.11 | -0.21 | -0.21 | — | -0.34 | -0.30 | -0.41 | — |
| Weighted avg. shares (diluted) | 112.48M | 111.22M | 110.59M | — | 102.60M | 100.37M | 99.40M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $75.47M | $59.91M | $76.96M | $65.80M | $76.50M | $44.77M | $37.97M | $34.87M |
| Short-term investments | $63.23M | $112.88M | $129.55M | $190.22M | $214.60M | $262.51M | $316.58M | $380.38M |
| Current assets | $145.35M | $180.09M | $215.08M | $266.45M | $300.38M | $319.18M | $366.65M | $424.82M |
| PP&E, net | $7.66M | $8.91M | $9.93M | $10.84M | $12.71M | $13.91M | $16.21M | $17.14M |
| Total assets | $165.78M | $202.85M | $239.92M | $293.24M | $335.29M | $356.42M | $408.30M | $468.30M |
| Current liabilities | $35.41M | $34.24M | $40.97M | $69.50M | $79.96M | $84.35M | $109.77M | $125.06M |
| Short-term debt | $0 | $9.85M | $1.48M | $366,000 | — | — | — | $0 |
| Long-term debt | $0 | $0 | $8.29M | $9.32M | $9.61M | $9.54M | $9.46M | $9.39M |
| Total debt | $0 | $9.85M | $9.77M | $9.69M | $9.61M | $9.54M | $9.46M | $9.39M |
| Total liabilities | $49.21M | $212.82M | $229.53M | $262.59M | $277.57M | $285.25M | $313.69M | $341.50M |
| Shareholders' equity | $116.57M | -$9.97M | $10.38M | $30.65M | $57.71M | $71.17M | $94.61M | $126.80M |
| Net debt | -$75.47M | -$50.07M | -$67.19M | -$56.11M | -$66.89M | -$35.23M | -$28.51M | -$25.48M |
| Shares outstanding | 112.27M | 111.66M | 111.03M | 110.36M | 107.45M | 101.21M | 99.99M | 99.09M |
| Cash flow statement | ||||||||
| Operating cash flow | -$24.15M | -$34.22M | -$49.81M | -$41.69M | -$32.51M | -$49.05M | -$60.78M | -$55.03M |
| Capital expenditure | $0 | $31,000 | $118,000 | $0 | $11,000 | $10,000 | $20,000 | $173,000 |
| Free cash flow | -$24.15M | -$34.25M | -$49.93M | -$41.69M | -$32.52M | -$49.06M | -$60.80M | -$55.20M |
| Investing cash flow | $50.09M | $17.12M | $60.95M | $25.60M | $49.54M | $55.72M | $65.73M | $41.40M |
| Financing cash flow | -$10.38M | $50,000 | $25,000 | $5.39M | $14.70M | $122,000 | $0 | $9.79M |
| Depreciation & amortization | $981,000 | $1.05M | $1.08M | $1.17M | $1.24M | $2.33M | $984,000 | $1.24M |
| Stock-based compensation | $2.00M | $2.61M | $2.91M | $4.84M | $6.40M | $7.06M | $8.35M | $10.21M |
Free plan shows the latest 8 periods; Pro shows all 35 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.